CLINICAL TRIALS
At the Neuromuscular Research Center, we participate in planning and carrying out research that may benefit patients that we typically see. We also do our best to stay informed about the research that other organizations are conducting so that we can provide our patients with as many treatment options as possible.
We currently have studies enrolling or soon to be enrolling for the following diseases and/or complications of these diseases. Please call the research coordinator at 480-314-1007 ext. 6 for more information.
- A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
- Study Details | A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis | ClinicalTrials.go
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis
- Study Details | A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis | ClinicalTrials.gov
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
- Study Details | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | ClinicalTrials.gov
- A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants Receiving Standard of Care (NEPTUNIA)
- Study Details | Study of M5049 in DM and PM Participants (NEPTUNIA) | ClinicalTrials.gov
- A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)
- Study Details | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis | ClinicalTrials.gov
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050.
- Study Details | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | ClinicalTrials.gov
- Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Study Details | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | ClinicalTrials.gov
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) – The RECLAIIM Study
- Study Details | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) | ClinicalTrials.gov